Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats

Biochemical Pharmacology

Volumn 74, Issue 8, 2007, Pages 1299-1307

  Liechti, Matthias E ^a   Markou, Athina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dependence; Intracranial self stimulation; LY379268; Metabotropic 2 3 glutamate receptor agonist; Nicotine; Rat; Reward; Withdrawal

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; NICOTINE; NICOTINE TARTRATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DYSFUNCTION; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; EMOTION; EVOKED SOMATOSENSORY RESPONSE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; REWARD; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; MALE; NICOTINE; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; REWARD; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34548685030     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.020     Document Type: Article

References (47)

1. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 (1986) 289-294
2. APA. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
3. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., and Fenwick J.W. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 48 (1991) 52-59
4. Kenny P.J., and Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 70 (2001) 531-549
5. Shiffman S., Hickcox M., Paty J.A., Gnys M., Kassel J.D., and Richards T.J. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 64 (1996) 993-1002
6. Epping-Jordan M.P., Watkins S.S., Koob G.F., and Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393 (1998) 76-79
7. Malin D.H. Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav 70 (2001) 551-559
8. Hildebrand B.E., Panagis G., Svensson T.H., and Nomikos G.G. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21 (1999) 560-574
9. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299 (2001) 12-20
10. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42 (1999) 1027-1040
11. Karasawa J., Yoshimizu T., and Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett 393 (2006) 127-130
12. Kalivas P.W. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 4 (2004) 23-29
13. Kenny P.J., and Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 25 (2004) 265-272
14. Markou A. Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression?. Biol Psychiatry 61 (2007) 17-22
15. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46 (2004) 457-467
16. Yoshimizu T., Shimazaki T., Ito A., and Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186 (2006) 587-593
17. Iijima M., Shimazaki T., Ito A., and Chaki S. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berl) 190 (2007) 233-239
18. Kenny P.J., Gasparini F., and Markou A. Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306 (2003) 1068-1076
19. Rodd Z.A., McKinzie D.L., Bell R.L., McQueen V.K., Murphy J.M., Schoepp D.D., et al. The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats. Behav Brain Res 171 (2006) 207-215
20. Peters J., and Kalivas P.W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) 186 (2006) 143-149
21. Baptista M.A., Martin-Fardon R., and Weiss F. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J Neurosci 24 (2004) 4723-4727
22. Bossert J.M., Busch R.F., and Gray S.M. The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking. Neuroreport 16 (2005) 1013-1016
23. Bossert J.M., Gray S.M., Lu L., and Shaham Y. Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-Induced relapse to heroin seeking. Neuropsychopharmacology 10 (2006) 2197-2209
24. Bossert J.M., Liu S.Y., Lu L., and Shaham Y. A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking. J Neurosci 24 (2004) 10726-10730
25. Liechti M.E., and Markou A. The mGlu2/3 receptor agonist LY379268 decreases nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats. Biol Psychiatry 61 (2007) 217S
26. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic, San Diego
27. Kornetsky C., and Esposito R.U. Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38 (1979) 2473-2476
28. Markou A., and Koob G.F. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51 (1992) 111-119
29. Kornetsky C., Esposito R.U., McLean S., and Jacobson J.O. Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry 36 (1979) 289-292
30. Watkins S.S., Stinus L., Koob G.F., and Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292 (2000) 1053-1064
31. Markou A., Kosten T.R., and Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18 (1998) 135-174
32. Backstrom P., and Hyytia P. Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG. Eur J Pharmacol 528 (2005) 110-118
33. Baptista M.A., Martin-Fardon R., and Weiss F. Effects of LY379268, an mGlu2/3 agonist, on cocaine self-administration and cocaine prime-induced cocaine seeking behavior in cocaine-escalated versus nonescalated rats. Soc Neurosci Abstr 31 (2005) 561-563
34. Hildebrand B.E., Nomikos G.G., Hertel P., Schilstrom B., and Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779 (1998) 214-225
35. Rada P., Jensen K., and Hoebel B.G. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology (Berl) 157 (2001) 105-110
36. Kew J.N., and Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179 (2005) 4-29
37. Xi Z.X., Baker D.A., Shen H., Carson D.S., and Kalivas P.W. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J Pharmacol Exp Ther 300 (2002) 162-171
38. Cornish J.L., and Kalivas P.W. Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci 20 (2000) RC89
39. Kalivas P.W., McFarland K., Bowers S., Szumlinski K., Xi Z.X., and Baker D. Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci 1003 (2003) 169-175
40. Robbe D., Alonso G., Chaumont S., Bockaert J., and Manzoni O.J. Role of p/q-Ca2+ channels in metabotropic glutamate receptor 2/3-dependent presynaptic long-term depression at nucleus accumbens synapses. J Neurosci 22 (2002) 4346-4356
41. Paterson N.E., Semenova S., Gasparini F., and Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167 (2003) 257-264
42. Paterson N.E., and Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) 179 (2005) 255-261
43. Liechti M.E., and Markou A. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol 554 (2007) 164-174
44. Bespalov A.Y., Dravolina O.A., Sukhanov I., Zakharova E., Blokhina E., Zvartau E., et al. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49 Suppl 1 (2005) 167-178
45. Harrison A.A., Gasparini F., and Markou A. Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) 160 (2002) 56-66
46. Skjei K.L., and Markou A. Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacology (Berl) 168 (2003) 280-292
47. Markou A., and Paterson N.E. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 3 (2001) 361-373